 SAN FRANCISCO and SAN DIEGO, Dec. 07, 2020 GLOBE NEWSWIRE -- Kinnate Biopharma Inc. Nasdaq: KNTE Kinnate, a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced the closing of its initial public offering of 13,800,000 shares of its common stock, which includes the exercise in full of the underwriters option to purchase 1,800,000 additional shares of its common stock, at a price to the public of 20.00 per share. Including the option exercise, the aggregate gross proceeds from the offering were 276.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares were offered by Kinnate. The shares began trading on The Nasdaq Global Select Market on December 3, 2020, under the symbol KNTE. 